Comparative Pharmacology
Head-to-head clinical analysis: ATRACURIUM BESYLATE PRESERVATIVE FREE versus METOCURINE IODIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATRACURIUM BESYLATE PRESERVATIVE FREE versus METOCURINE IODIDE.
ATRACURIUM BESYLATE PRESERVATIVE FREE vs METOCURINE IODIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nondepolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at nicotinic cholinergic receptors at the neuromuscular junction, preventing depolarization and muscle contraction. Degraded via Hofmann elimination (non-enzymatic) and ester hydrolysis.
Competitive nicotinic acetylcholine receptor antagonist at the neuromuscular junction, blocking acetylcholine binding and preventing muscle contraction.
0.4-0.5 mg/kg IV bolus for intubation; maintenance: 0.08-0.1 mg/kg IV every 15-25 min or continuous infusion 5-10 mcg/kg/min
Initial dose 0.2 mg/kg IV; maintenance doses of 0.1-0.15 mg/kg IV as needed for neuromuscular blockade.
None Documented
None Documented
Terminal elimination half-life of atracurium is approximately 20 minutes (range 15-35 min) in healthy adults; clinically, this short half-life correlates with rapid spontaneous recovery without the need for reversal agents, though prolonged in hypothermia or acidosis.
Terminal elimination half-life: 3-5 hours in patients with normal renal function. Prolonged in renal impairment.
Primarily via Hofmann elimination (non-enzymatic degradation) and ester hydrolysis; renal excretion accounts for less than 10% unchanged, with biliary/fecal elimination minimal. Approximately 40% as laudanosine and other metabolites via urine, with laudanosine further metabolized and renally excreted.
Renal: 85-90% unchanged; biliary/fecal: <5%.
Category C
Category C
Neuromuscular Blocker
Neuromuscular Blocker